

## Message from the President



Spring is just around the corner where I reside and it's most welcome after a long "traditional" winter with deep snow and extreme cold. As the seasons change, we are reminded about the cycles of our animal friends as well. In the article below,

we discuss breeding season in North America which is now getting underway. In our Australian market, breeding and foaling season are over for now. Our immunotherapy for equine endometritis plays an important role during these times.

Spring signifies calving season in our bovine market. Amplimune immunotherapy, our non-antibiotic treatment for calf scours, is important to introduce soon after birth to protect calves from environmental pathogens at this vulnerable time.

Equimune—our antiviral therapy for the treatment of equine respiratory disease complex—is often used in performance horses at times of travel and competition. Much of this activity occurs from spring to fall in North America (with seasonal variances according to climate).

Our anticancer products—Immunocidin for dogs and Immunocidin Equine for horses—are not considered "seasonal" products as cancer can occur at any time of year. Equine sarcoids can be more noticeable in warmer months when blankets are removed.

No matter the season, NovaVive is here to offer support.

## It's Settle® season in North America

Breeding season means Settle® season. Settle is our immunotherapy for the treatment of equine endometritis, which often gets in the way of successful breeding.

Settle is manufactured using the NovaVive Mycobacterium cell wall fraction (MCWF) technology. It is regulator-approved as an aid in the treatment of equine endometritis caused by *Streptococcus zooepidemicus*, the hardest to treat cause of the disease.

Settle is approved and available in the USA, Canada, Australia and UAE. This is its time to shine in North America since horse owners and breeders are seeking to maximize the reproductive success of their mares.

Extensive research with Settle has shown that it can be effective in a variety of situations, including:

1. In the face of bacterial challenge with *Streptococcus zooepidemicus* (Rogan *et al*), treatment with Settle resulted in elimination of endometritis in 70% of mares at 7 days post-ovulation.


2. Settle significantly reduced the magnitude of bacterial growth in the uterus (Fedorka *et al.*). Settle-treated mares had a significant decrease in the number of days it required to clean culture.

3. Settle has been shown to hasten the uterine involution process when administered post-foaling, allowing the mare to be ready faster for the next breeding cycle.

4. A two-treatment regimen of Settle (6ml per treatment) proved effective in treating endometrial cups. There has been no other effective treatment identified to date.

It's interesting to note that the Australian Veterinary Association launched Australia's first nationally endorsed Antimicrobial Prescribing Guidelines for Horses in September, 2025 as a guide to best practices in the field. In its chapter about endometritis, the Guidelines refer to Settle as follows:

*Bacterial extracts, such as Mycobacterium phlei cell wall extract (Settle), have been used to enhance the innate humoral immune*



*response by decreasing pro-inflammatory cytokines and increasing anti-inflammatory cytokine production. Mares treated with this product had reduced immune cell infiltration into the uterus, mimicking the immune response of a resistant mare. This immune stimulant can be administered to the broodmare as part of the routine breeding management of the mare to normalise the immune response to breeding.*

Settle has proven safe when administered with natural breeding or artificial insemination.

# Employee profile: Greta Bettis



We often reference our valued employees, but we don't often talk about them in detail. We're pleased to introduce this feature in our quarterly newsletter focused on our hardworking employees. In this edition, we learn more about Greta Bettis, Packaging Technician at NovaVive USA in Athens, Georgia.

**Q:** How long have you worked at Nova-Vive?

**A:** I have been here for 3 years and a few months.

**Q:** What did you do before joining Nova-Vive?

**A:** Actually, I used to work right next door doing merchandising and sales for a band called Widespread Panic here in Athens that toured all over the U.S. That is how I originally met Lynn and the other folks who worked here when the company was Bioniche.

**Q:** What is your background/education?

**A:** I grew up in the next county over from Athens and graduated from high school in 1978. I worked and took night classes at the University of Georgia, but did not finish a degree.

**Q:** What do you like most about your job?

**A:** I really enjoy the people I work with. We all get along very well and when we are extremely busy, we help each other out. We have a great team.

**Q:** What makes you most proud about your work?

**A:** I love animals. What we do to help the wellbeing of dogs, horses, cows and sometimes even exotic animals gives me great pleasure and pride about what our products can do for them.

**Q:** What is the greatest challenge at work?

**A:** My job is packaging and I've been doing this job for long enough that everything goes well. There are certain products that require some extra time and that can be somewhat challenging at times.

**Q:** If you were to have done something else for work, what would it have been?

**A:** I would have been an antique appraiser.

**Q:** What is your favourite hobby in your down time?

**A:** I love antiques and enjoy going to antique stores, estate sales, and sometimes auctions. I also enjoy being home with my dog, Levi and my cat, Milkshake. I adopted them from sad situations, so they need extra love and attention.

## Is it Equimune® or EqStim®?

When two products are similarly named and have similar properties, they often get confused in the market. Our immunotherapy for equine respiratory disease complex (ERDC) - Equimune—is often mixed up with another company's product—EqStim. Both products are regulator-approved in the U.S. and are intended for treating the same condition. However, there are differences between the two.

Equimune is manufactured using a non-disease causing mycobacterium (*Mycobacterium phlei*) whereas EqStim is made from a pathogenic organism—(*Propionibacterium acnes*).

Equimune is approved as a standalone injectable treatment and EqStim is approved as an adjunct therapy with antibiotics or hyperimmune therapy. Both are administered by intravenous injection.

Equimune is approved as a one-dose treatment whereas EqStim requires three or more doses per treatment.

Equimune is processed as cell wall fractions (small particle size to reduce side effects). EqStim is made with inactivated whole cells.


The mode of action of Equimune is both antiviral and immune response. EqStim promotes immune response.

It is unknown if EqStim is safe to use at the time of breeding, whereas Equimune has proven safe and effective in mares at time of breeding and when pregnant.

Equimune offers the added benefit of reducing antibiotic use, whereas EqStim requires antibiotic therapy at the same time.

## Treating cancer in a parrot

Dr. Melissa McNally of Jolly Road Veterinary Hospital in Lansing, MI approached NovaVive about a client's 16-year-old Blue-fronted Amazon parrot (Fredrica) with a malignant oral mass suspected to be squamous cell carcinoma. Dr. McNally wondered if Immunocidin® - our anticancer immunotherapy for dogs—might help Fredrica.



Immunocidin treatment was started experimentally in November, 2025 by infusing Fredrica's water with product. After an initial small weight loss, she gained the weight back.

After several well-tolerated treatments, Fredrica decided she no longer liked the medicated water so her guardian began squirting small amounts by syringe into her mouth.

Dr. McNally commented that the tumor seemed to be slowly responding to Immunocidin therapy, however, due to other health issues, Fredrica passed away on March 11th. "We were able to give Fredrica an extra 5 months from her diagnosis with Immunocidin therapy," added Dr. McNally.